HILLSIDE, NJ, April 30, 2007 (PRIME NEWSWIRE) -- InB:Biotechnologies, Inc. (“INB:B”), a wholly-owned subsidiary of Integrated BioPharma (Nasdaq:INBP), announced today that it successfully produced a bioequivalent diabetes-associated autoantigen using INBP’s novel, proprietary AIPwLV platform technology. The study was conducted by the Fraunhofer USA Center for Molecular Biotechnology (CMB), the Contract Research Organization led by Dr. Vidadi Yusibov, through which INB:B executes its vaccine and other biopharmaceutical development activities.
